Waterfront Wealth Inc. Acquires 137 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Waterfront Wealth Inc. grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,675 shares of the specialty pharmaceutical company’s stock after purchasing an additional 137 shares during the quarter. Waterfront Wealth Inc.’s holdings in Jazz Pharmaceuticals were worth $1,191,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. UMB Bank n.a. grew its stake in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 129 shares in the last quarter. Itau Unibanco Holding S.A. boosted its holdings in shares of Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 206 shares in the last quarter. Venturi Wealth Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares during the last quarter. Finally, Versant Capital Management Inc boosted its stake in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 350 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on JAZZ. TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, Robert W. Baird increased their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Buy” and an average price target of $180.33.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders sold 5,053 shares of company stock valued at $617,442. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $136.84 on Friday. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $138.27. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $8.27 billion, a P/E ratio of 19.27, a P/E/G ratio of 1.03 and a beta of 0.56. The stock has a 50 day moving average price of $124.59 and a 200 day moving average price of $117.82.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.